Drug Development
Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the protocol was developed with former FDA leaders.
FEATURED STORIES
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
Celebrities’ struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health’s elacestrant are on the horizon.
The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.
A study conducted by Athersys’ partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
The FDA has a few target action dates for the end of the month, although PDUFA dates can sometimes seem like a moving target.
Zealand Pharma shared positive top-line results for its second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.